首页 > 最新文献

Euroasian Journal of Hepato-Gastroenterology最新文献

英文 中文
A Prospective Clinicoendoscopic Follow-up Study in Young Patients with Peptic Ulcer Perforation at a Tertiary Institute in Central India. 一项前瞻性临床内镜随访研究在年轻患者消化性溃疡穿孔在印度中部的一个高等研究所。
Pub Date : 2019-07-01 DOI: 10.5005/jp-journals-10018-1306
Deepa Jahagirdaar, Nitin Bomanwar, Sneha Joshi

Background: Perforation peritonitis is one of the commonest encountered emergencies in the surgery casualty. This study was conducted with the aim of identifying risk factors in peptic ulcer disease (PUD) in young patients.

Materials and methods: Seventy patients were evaluated in this study and were followed up with clinical examination and endoscopy at 8 weeks and 6 months.

Results: Out of the total 70 patients, there was a mortality of 5 patients and 7 patients were lost to follow-up. Out of the remaining 57 patients, 56 were men and 1 was a woman. Maximum patients were from the age group of 35-40 years. The patients were categorized on the basis of their clinical symptoms and endoscopy results at the follow-up of 6 months in 4 categories-21 patients having an active ulcer and symptomatic, 15 patients having active ulcer but no symptoms, 16 patients who were asymptomatic and without an active ulcer and 5 patients nonulcer dyspepsia.

Conclusion: Postoperative treatment with H2 blockers or proton pump inhibiters along with anti-Helicobacter pylori regimen should be prescribed for all patients with peptic ulcer perforation. Routine endoscopic examination of such patients should also form a part of the follow-up to look for ulcer healing postoperatively.

How to cite this article: Jahagirdaar D, Bomanwar N, Joshi S. A Prospective Clinicoendoscopic Follow-up Study in Young Patients with Peptic Ulcer Perforation at a Tertiary Institute in Central India. Euroasian J Hepato-Gastroenterol 2019;9(2):91-95.

背景:穿孔性腹膜炎是外科伤员中最常见的急症之一。本研究旨在确定年轻患者消化性溃疡疾病(PUD)的危险因素。材料与方法:本研究对70例患者进行评估,分别于8周和6个月进行临床检查和内镜检查随访。结果:70例患者中,死亡5例,失访7例。在剩下的57名患者中,有56名男性和1名女性。最多患者年龄在35-40岁之间。根据患者的临床症状和随访6个月的内镜检查结果将患者分为4类:有活动性溃疡且有症状的患者21例,有活动性溃疡但无症状的患者15例,无症状且无活动性溃疡的患者16例,非溃疡性消化不良的患者5例。结论:所有消化性溃疡穿孔患者术后均应给予H2阻滞剂或质子泵抑制剂联合抗幽门螺杆菌方案治疗。这类患者的常规内镜检查也应成为随访的一部分,以寻找溃疡的术后愈合情况。Jahagirdaar D, Bomanwar N, Joshi S.在印度中部一所高等医学研究所对年轻消化性溃疡穿孔患者的前瞻性临床内镜随访研究。中华肝病杂志;2019;9(2):91-95。
{"title":"A Prospective Clinicoendoscopic Follow-up Study in Young Patients with Peptic Ulcer Perforation at a Tertiary Institute in Central India.","authors":"Deepa Jahagirdaar, Nitin Bomanwar, Sneha Joshi","doi":"10.5005/jp-journals-10018-1306","DOIUrl":"10.5005/jp-journals-10018-1306","url":null,"abstract":"<p><strong>Background: </strong>Perforation peritonitis is one of the commonest encountered emergencies in the surgery casualty. This study was conducted with the aim of identifying risk factors in peptic ulcer disease (PUD) in young patients.</p><p><strong>Materials and methods: </strong>Seventy patients were evaluated in this study and were followed up with clinical examination and endoscopy at 8 weeks and 6 months.</p><p><strong>Results: </strong>Out of the total 70 patients, there was a mortality of 5 patients and 7 patients were lost to follow-up. Out of the remaining 57 patients, 56 were men and 1 was a woman. Maximum patients were from the age group of 35-40 years. The patients were categorized on the basis of their clinical symptoms and endoscopy results at the follow-up of 6 months in 4 categories-21 patients having an active ulcer and symptomatic, 15 patients having active ulcer but no symptoms, 16 patients who were asymptomatic and without an active ulcer and 5 patients nonulcer dyspepsia.</p><p><strong>Conclusion: </strong>Postoperative treatment with H<sub>2</sub> blockers or proton pump inhibiters along with anti-<i>Helicobacter pylori</i> regimen should be prescribed for all patients with peptic ulcer perforation. Routine endoscopic examination of such patients should also form a part of the follow-up to look for ulcer healing postoperatively.</p><p><strong>How to cite this article: </strong>Jahagirdaar D, Bomanwar N, Joshi S. A Prospective Clinicoendoscopic Follow-up Study in Young Patients with Peptic Ulcer Perforation at a Tertiary Institute in Central India. Euroasian J Hepato-Gastroenterol 2019;9(2):91-95.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"9 2","pages":"91-95"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5a/e7/ejohg-9-91.PMC7047314.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37693908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predictors of Three-month Hospital Readmissions and Mortality in Patients with Cirrhosis of Liver. 肝硬化患者三个月内再次住院和死亡率的预测因素。
Pub Date : 2019-07-01 DOI: 10.5005/jp-journals-10018-1302
Anurag Lavekar, Dhananjay Raje, Aarsha Sadar, Tanuja Manohar, Kavutharapu Sri Manjari, Pradeep T Satyanarayana

Background: The rate of readmission to the hospital and mortality within 3 months is used as a quality measure for hospitalized patients with advanced liver disease; however, the topic has not been studied adequately under Indian context.

Materials and methods: This study was a longitudinal study conducted from March 2017 to March 2018. Patients admitted with liver cirrhosis at inpatient hepatology service in Tertiary Health Care Centre, Mysore, India, were included for the study. A total of 232 patients were studied and their demographic, clinical, biochemical parameters along with readmission status and outcomes within 3 months of observation were recorded. The effect of these factors on readmission and mortality was studied through multivariate logistic regression.

Results: The risk of readmission within 3 months was significantly associated with the presence of hydrothorax, hepatorenal syndrome (HRS), and portal vein thrombosis (PVT). Maddrey's discriminant function (DF), model for end-stage liver disease (MELD) score, and the Child-Turcotte-Pugh (CTP) C grade also significantly increased the odds of readmission. The area under curve (AUC) for DF and MELD were 0.927 and 0.928, respectively. Both DF and MELD significantly increased the odds of mortality.

Conclusion: The present study revealed that the parameters such as MELD and DF score and complications such as hydrothorax, HRS, and PVT are the most predictive indicators of cirrhosis complication to ascertain the rate of readmission and mortality within 3 months of patient discharge.

How to cite this article: Lavekar A, Raje D, Sadar A, et al. Predictors of Three-month Hospital Readmissions and Mortality in Patients with Cirrhosis of Liver. Euroasian J Hepato-Gastroenterol 2019;9(2):71-77.

背景:3个月内再入院率和死亡率被用作晚期肝病住院患者的质量衡量标准;然而,印度尚未对这一主题进行充分研究:本研究是一项纵向研究,时间为 2017 年 3 月至 2018 年 3 月。研究对象包括印度迈索尔三级医疗保健中心肝病住院服务处收治的肝硬化患者。共研究了 232 名患者,并记录了他们的人口统计学、临床、生化参数以及再入院情况和观察 3 个月内的结果。通过多变量逻辑回归研究了这些因素对再入院和死亡率的影响:结果:3个月内再入院的风险与胸水、肝肾综合征(HRS)和门静脉血栓形成(PVT)的存在明显相关。Maddrey判别函数(DF)、终末期肝病模型(MELD)评分和Child-Turcotte-Pugh(CTP)C级也会显著增加再入院的几率。DF和MELD的曲线下面积(AUC)分别为0.927和0.928。DF和MELD都会明显增加死亡率:本研究显示,MELD 和 DF 评分等参数以及胸水、HRS 和 PVT 等并发症是肝硬化并发症的最佳预测指标,可用于确定患者出院后 3 个月内的再入院率和死亡率:Lavekar A, Raje D, Sadar A, et al. Predictors of Three-month Hospital Readmissions and Mortality in Patients with Cirrhosis of Liver.Euroasian J Hepato-Gastroenterol 2019;9(2):71-77.
{"title":"Predictors of Three-month Hospital Readmissions and Mortality in Patients with Cirrhosis of Liver.","authors":"Anurag Lavekar, Dhananjay Raje, Aarsha Sadar, Tanuja Manohar, Kavutharapu Sri Manjari, Pradeep T Satyanarayana","doi":"10.5005/jp-journals-10018-1302","DOIUrl":"10.5005/jp-journals-10018-1302","url":null,"abstract":"<p><strong>Background: </strong>The rate of readmission to the hospital and mortality within 3 months is used as a quality measure for hospitalized patients with advanced liver disease; however, the topic has not been studied adequately under Indian context.</p><p><strong>Materials and methods: </strong>This study was a longitudinal study conducted from March 2017 to March 2018. Patients admitted with liver cirrhosis at inpatient hepatology service in Tertiary Health Care Centre, Mysore, India, were included for the study. A total of 232 patients were studied and their demographic, clinical, biochemical parameters along with readmission status and outcomes within 3 months of observation were recorded. The effect of these factors on readmission and mortality was studied through multivariate logistic regression.</p><p><strong>Results: </strong>The risk of readmission within 3 months was significantly associated with the presence of hydrothorax, hepatorenal syndrome (HRS), and portal vein thrombosis (PVT). Maddrey's discriminant function (DF), model for end-stage liver disease (MELD) score, and the Child-Turcotte-Pugh (CTP) C grade also significantly increased the odds of readmission. The area under curve (AUC) for DF and MELD were 0.927 and 0.928, respectively. Both DF and MELD significantly increased the odds of mortality.</p><p><strong>Conclusion: </strong>The present study revealed that the parameters such as MELD and DF score and complications such as hydrothorax, HRS, and PVT are the most predictive indicators of cirrhosis complication to ascertain the rate of readmission and mortality within 3 months of patient discharge.</p><p><strong>How to cite this article: </strong>Lavekar A, Raje D, Sadar A, <i>et al</i>. Predictors of Three-month Hospital Readmissions and Mortality in Patients with Cirrhosis of Liver. Euroasian J Hepato-Gastroenterol 2019;9(2):71-77.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"9 2","pages":"71-77"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/89/c1/ejohg-9-71.PMC7047310.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37692975","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment by Transarterial Chemoembolization and Sorafenib for Hepatocellular Carcinoma vs Advanced Hepatocellular Carcinoma in Bangladesh: A Real-life Situation. 在孟加拉国,经动脉化疗栓塞和索拉非尼治疗肝细胞癌与晚期肝细胞癌:现实生活中的情况。
Pub Date : 2019-07-01 DOI: 10.5005/jp-journals-10018-1300
Mamun Al Mahtab, Md Abdur Rahim, Sheikh Mohammad Noor-E-Alam, Mohammad Ashraful Alam, Faiz Ahmad Khondaker, Ahmed Lutful Moben, Jhumur Ghosh, Md Sakirul Islam Khan

Background: Although there are thousands of patients with hepatocellular carcinoma (HCC) in Bangladesh, almost there is no nationwide recommendations for therapeutic maneuver for HCC patients. As most of the HCC patients of Bangladesh are diagnosed late, patients with advanced HCC with large and multiple HCC nodules represent the usual presentation of HCC. The study is presented here to assess the effects of a combined therapy of transarterial chemoembolization (TACE) and sorafenib in advanced HCC patients.

Materials and methods: A total of 77 patients with advanced HCC were enrolled in this study. All of them had advanced HCC with variable etiologies and clinical conditions. All patients were treated by TACE and also given systemic sorafenib at the same time. The patients were checked 1 and 3 months after therapy commencement.

Results: Out of 77 patients, 18 patients died within 1 month and additional 15 patients died within 3 months after therapy commencement. Thus, there remains 44 surviving patients after 3 months. When different parameters of dead patients and survived patients were compared, no specific parameters dictated the factors about overall survival of more than 3 months.

Discussion: This is the first approach to initiate an invasive and a systemic therapy for treatment of advanced HCC in Bangladesh. Further follow-up of patients and their long-term overall survival may cast some lights about the role of these therapies in Bangladeshi HCC patients.

How to cite this article: Al Mahtab, M, Rahim MA, Noor-E-Alam SM, et al. Treatment by Transarterial Chemoembolization and Sorafenib for Hepatocellular Carcinoma vs Advanced Hepatocellular Carcinoma in Bangladesh: A Real-life Situation. Euroasian J Hepato-Gastroenterol 2019;9(2):63-66.

背景:尽管孟加拉国有成千上万的肝细胞癌(HCC)患者,但几乎没有全国性的HCC患者治疗策略推荐。由于孟加拉国大多数HCC患者诊断较晚,晚期HCC患者伴大结节和多发结节是HCC的常见表现。该研究旨在评估经动脉化疗栓塞(TACE)和索拉非尼联合治疗晚期HCC患者的效果。材料与方法:共纳入77例晚期HCC患者。所有患者均为晚期HCC,病因和临床情况各不相同。所有患者均接受TACE治疗,同时给予全身索拉非尼。治疗开始后1个月和3个月对患者进行检查。结果:77例患者中,18例患者在治疗开始后1个月内死亡,15例患者在治疗开始后3个月内死亡。因此,3个月后仍有44名患者存活。在比较死亡患者和存活患者的不同参数时,没有特定的参数决定3个月以上总生存的因素。讨论:这是孟加拉国首个启动侵入性和系统性治疗晚期HCC的方法。对患者的进一步随访和他们的长期总体生存可能会对这些治疗在孟加拉国HCC患者中的作用有所启发。如何引用本文:Al Mahtab, M, Rahim MA, Noor-E-Alam SM,等。在孟加拉国,经动脉化疗栓塞和索拉非尼治疗肝细胞癌与晚期肝细胞癌:现实生活中的情况。中华肝病杂志2019;9(2):63-66。
{"title":"Treatment by Transarterial Chemoembolization and Sorafenib for Hepatocellular Carcinoma vs Advanced Hepatocellular Carcinoma in Bangladesh: A Real-life Situation.","authors":"Mamun Al Mahtab,&nbsp;Md Abdur Rahim,&nbsp;Sheikh Mohammad Noor-E-Alam,&nbsp;Mohammad Ashraful Alam,&nbsp;Faiz Ahmad Khondaker,&nbsp;Ahmed Lutful Moben,&nbsp;Jhumur Ghosh,&nbsp;Md Sakirul Islam Khan","doi":"10.5005/jp-journals-10018-1300","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1300","url":null,"abstract":"<p><strong>Background: </strong>Although there are thousands of patients with hepatocellular carcinoma (HCC) in Bangladesh, almost there is no nationwide recommendations for therapeutic maneuver for HCC patients. As most of the HCC patients of Bangladesh are diagnosed late, patients with advanced HCC with large and multiple HCC nodules represent the usual presentation of HCC. The study is presented here to assess the effects of a combined therapy of transarterial chemoembolization (TACE) and sorafenib in advanced HCC patients.</p><p><strong>Materials and methods: </strong>A total of 77 patients with advanced HCC were enrolled in this study. All of them had advanced HCC with variable etiologies and clinical conditions. All patients were treated by TACE and also given systemic sorafenib at the same time. The patients were checked 1 and 3 months after therapy commencement.</p><p><strong>Results: </strong>Out of 77 patients, 18 patients died within 1 month and additional 15 patients died within 3 months after therapy commencement. Thus, there remains 44 surviving patients after 3 months. When different parameters of dead patients and survived patients were compared, no specific parameters dictated the factors about overall survival of more than 3 months.</p><p><strong>Discussion: </strong>This is the first approach to initiate an invasive and a systemic therapy for treatment of advanced HCC in Bangladesh. Further follow-up of patients and their long-term overall survival may cast some lights about the role of these therapies in Bangladeshi HCC patients.</p><p><strong>How to cite this article: </strong>Al Mahtab, M, Rahim MA, Noor-E-Alam SM, <i>et al</i>. Treatment by Transarterial Chemoembolization and Sorafenib for Hepatocellular Carcinoma vs Advanced Hepatocellular Carcinoma in Bangladesh: A Real-life Situation. Euroasian J Hepato-Gastroenterol 2019;9(2):63-66.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"9 2","pages":"63-66"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/67/5e/ejohg-9-63.PMC7047312.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37692973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Surveillance of Hepatitis Viruses in Several Small Islands of Japan by Ship: A Public Health Approach for Elimination of Hepatitis Viruses by 2030. 日本几个小岛屿的船舶肝炎病毒监测:到2030年消除肝炎病毒的公共卫生方法。
Pub Date : 2019-07-01 DOI: 10.5005/jp-journals-10018-1304
Tomohiro Akao, Morikazu Onji, Keitarou Kawasaki, Takahide Uehara, Yukima Kuwabara, Takashi Nishimoto, Shinji Yamamoto, Jiro Miyaike, Masaki Oomoto, Teruki Miyake

Aim: In 1990, an epidemiological survey by ship in some Japanese islands revealed high prevalence of hepatitis viruses and human T cell leukemia virus (HTLV). A second prevalence study of these viruses were accomplished in 2018, 28 years after initial survey. Analysis of these studies provide insights about strategies of elimination of hepatitis viruses at remote areas.

Materials and methods: In 2018, prevalence of hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), and HTLV was checked in 305 subjects in the islands those covered in 1990's survey. Hepatitis A virus was checked by the presence of anti-HAV IgG in sera; HBV was affirmed when hepatitis B surface antigen (HBsAg) in sera. Hepatitis C virus infection was evaluated by the presence of antibody to HCV (anti-HCV) and infection with HTLV was estimated by immunoassay. The methodology of assessment of different hepatitis viruses were optimized on the basis of present scientific knowhow.

Results: In 1990, the prevalence of HAV (presence of anti-HAV), HBV (presence of HBsAg), HCV (positivity for anti-HCV), and HTLV was found in 79.3%, 11.1%, 2.2%, and 3.3% of apparently health subjects of the islands, respectively. The prevalence of HAV, HBV, HCV, and HTLV was 47.9%, 4.6%, 1.0%, and 3.0%, respectively, in 2018. A shift of age of infected persons tilted towards right as the days progressed.

Conclusion: The study indicates a scenario of elimination of hepatitis viruses in Japan as lower trends of prevalence of HAV, HBV, and HCV have been recorded in 2018 compared with 1990, mainly by preventive measures. The most notable finding is that there are almost no new case below the age of 40 years, indicating an effective containment measure against these viruses.

How to cite this article: Akao T, Onji M, Kawasaki K, et al. Surveillance of Hepatitis Viruses in Several Small Islands of Japan by Ship: A Public Health Approach for Elimination of Hepatitis Viruses by 2030. Euroasian J Hepato-Gastroenterol 2019;9(2):57-62.

目的:1990年,日本部分岛屿的船舶流行病学调查显示肝炎病毒和人T细胞白血病病毒(HTLV)高发。2018年,在首次调查28年后,对这些病毒进行了第二次流行病学研究。对这些研究的分析提供了在偏远地区消除肝炎病毒战略的见解。材料与方法:2018年,对1990年调查覆盖的岛屿305名受试者进行了甲型肝炎病毒(HAV)、乙型肝炎病毒(HBV)、丙型肝炎病毒(HCV)和HTLV的流行情况检查。血清中抗甲肝IgG检测甲肝病毒;血清乙型肝炎表面抗原(HBsAg)是HBV的确认指标。丙型肝炎病毒感染通过HCV抗体(抗HCV)的存在来评估,HTLV感染通过免疫测定来评估。在现有科学知识的基础上,对不同肝炎病毒的评估方法进行了优化。结果:1990年海岛表面健康人群中,HAV(抗-HAV)、HBV (HBsAg)、HCV(抗-HCV阳性)和HTLV的患病率分别为79.3%、11.1%、2.2%和3.3%。2018年,HAV、HBV、HCV和HTLV的患病率分别为47.9%、4.6%、1.0%和3.0%。随着年龄的增长,感染者的年龄向右倾斜。结论:该研究表明,与1990年相比,日本2018年甲型肝炎、乙型肝炎和丙型肝炎的流行率呈下降趋势,主要是通过预防措施,日本有望消除肝炎病毒。最值得注意的发现是,40岁以下几乎没有新病例,这表明对这些病毒采取了有效的遏制措施。如何引用本文:Akao T, Onji M, Kawasaki K,等。日本几个小岛屿的船舶肝炎病毒监测:到2030年消除肝炎病毒的公共卫生方法。中华肝病杂志,2019;9(2):57-62。
{"title":"Surveillance of Hepatitis Viruses in Several Small Islands of Japan by Ship: A Public Health Approach for Elimination of Hepatitis Viruses by 2030.","authors":"Tomohiro Akao,&nbsp;Morikazu Onji,&nbsp;Keitarou Kawasaki,&nbsp;Takahide Uehara,&nbsp;Yukima Kuwabara,&nbsp;Takashi Nishimoto,&nbsp;Shinji Yamamoto,&nbsp;Jiro Miyaike,&nbsp;Masaki Oomoto,&nbsp;Teruki Miyake","doi":"10.5005/jp-journals-10018-1304","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1304","url":null,"abstract":"<p><strong>Aim: </strong>In 1990, an epidemiological survey by ship in some Japanese islands revealed high prevalence of hepatitis viruses and human T cell leukemia virus (HTLV). A second prevalence study of these viruses were accomplished in 2018, 28 years after initial survey. Analysis of these studies provide insights about strategies of elimination of hepatitis viruses at remote areas.</p><p><strong>Materials and methods: </strong>In 2018, prevalence of hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), and HTLV was checked in 305 subjects in the islands those covered in 1990's survey. Hepatitis A virus was checked by the presence of anti-HAV IgG in sera; HBV was affirmed when hepatitis B surface antigen (HBsAg) in sera. Hepatitis C virus infection was evaluated by the presence of antibody to HCV (anti-HCV) and infection with HTLV was estimated by immunoassay. The methodology of assessment of different hepatitis viruses were optimized on the basis of present scientific knowhow.</p><p><strong>Results: </strong>In 1990, the prevalence of HAV (presence of anti-HAV), HBV (presence of HBsAg), HCV (positivity for anti-HCV), and HTLV was found in 79.3%, 11.1%, 2.2%, and 3.3% of apparently health subjects of the islands, respectively. The prevalence of HAV, HBV, HCV, and HTLV was 47.9%, 4.6%, 1.0%, and 3.0%, respectively, in 2018. A shift of age of infected persons tilted towards right as the days progressed.</p><p><strong>Conclusion: </strong>The study indicates a scenario of elimination of hepatitis viruses in Japan as lower trends of prevalence of HAV, HBV, and HCV have been recorded in 2018 compared with 1990, mainly by preventive measures. The most notable finding is that there are almost no new case below the age of 40 years, indicating an effective containment measure against these viruses.</p><p><strong>How to cite this article: </strong>Akao T, Onji M, Kawasaki K, <i>et al</i>. Surveillance of Hepatitis Viruses in Several Small Islands of Japan by Ship: A Public Health Approach for Elimination of Hepatitis Viruses by 2030. Euroasian J Hepato-Gastroenterol 2019;9(2):57-62.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"9 2","pages":"57-62"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9b/ed/ejohg-9-57.PMC7047309.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37692972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
A Dynamic Mathematical Modeling Revelation about the Impact of Vaccination on Hepatitis B Virus-induced Infection and Death Rate in Bangladesh. 疫苗接种对孟加拉国乙型肝炎病毒感染和死亡率影响的动态数学模型揭示。
Pub Date : 2019-07-01 DOI: 10.5005/jp-journals-10018-1303
Sajib Chakraborty, Rajib Chakravorty, Saruar Alam, Yearul Kabir, Musarrat Mahtab, Md Atikul Islam, Md Abul Khair Yusuf, Ruksana Raihan, Mamun Al Mahtab, Sheikh Mohammad Fazle Akbar

Aim: Attainment of sustainable development goal (SDG) targets requires reducing the rate of new hepatitis B virus (HBV)-induced infection and mortality rate to 90% and 65%, respectively, by 2030. Therefore, it is important to investigate the feasibility of reducing the required rates of HBV-induced infection and death incidents at the current rate of vaccination coverage in Bangladesh. Moreover, factors influencing vaccination coverage like negative bias toward girls during immunization can affect the current vaccination program and ultimately hinder the efforts to reduce HBV-induced infection and death rates. To investigate the possibility of reducing HBV-induced infection and death rates with current vaccination coverage, we adopted mathematical molding-based approach.

Materials and methods: We developed a mathematical model based on the susceptible-infectious-recovered model to simulate the HBV-induced infection in children under the age of five at three different vaccination rates: 80, 90, and 95%. Additionally the impact of current vaccination coverage was assessed on HBV-induced death rates in the future. Moreover, we took advantage of the mathematical model to investigate the impact of negative bias toward girls in vaccination program on HBV-induced infection and death rates.

Results: The model simulations revealed that 10% increase in the vaccination rate from 80 to 90% can potentially contribute to the significant lowering (around 40%) of HBV-induced infection rate among children. When increased by 5% of vaccination rate from 90 to 95%, the HBV-infection rate is likely to be decreased by another 22%. Likewise, 44% reduction in HBV-induced death rate in the future (2050 onward) can potentially be achieved by 10% increase in the current vaccination rate from 80 to 90%, whereas 5% increase in the current vaccination rate (90-95%) may lead to 24% further reduction of death rate. These results underscored the significant impact of vaccination in reducing HBV-induced infection among children and future death rates in adults. Moreover, at 90% vaccination coverage, the negative bias of vaccination toward girls contributes to an increase of 15 and 12% of HBV-induced infection and death rates, respectively, in female subjects compared to their male counterparts.

Conclusion: The current vaccination coverage (80-90%) is further aggravated by untimely vaccination, dropouts from vaccination program, and negative bias toward girls in vaccination program. Therefore, if the current situation persists, it will not be possible to accomplish the required reduction in HBV-induced infection and death rates by 2030, according to the SDG guidelines. Moreover negative bias in the vaccination program may intensify the HBV-induced infection and death rates in the future.

Clinical significance: In light of the mathematical model, we suggest that the vacci

目标:实现可持续发展目标的具体目标需要到2030年将乙型肝炎病毒(HBV)引起的新感染率和死亡率分别降至90%和65%。因此,重要的是调查在孟加拉国目前的疫苗接种率下降低所需的乙肝病毒引起的感染率和死亡事件的可行性。此外,影响疫苗接种覆盖率的因素,如免疫接种期间对女孩的负面偏见,可能会影响当前的疫苗接种计划,并最终阻碍降低乙肝病毒引起的感染和死亡率的努力。为了研究在当前疫苗接种覆盖率下降低hbv诱导感染和死亡率的可能性,我们采用了基于数学建模的方法。材料和方法:我们建立了一个基于易感-感染-恢复模型的数学模型,以模拟五岁以下儿童在三种不同疫苗接种率(80%,90%和95%)下的hbv诱导感染。此外,还评估了当前疫苗接种覆盖率对未来hbv诱发死亡率的影响。此外,我们利用数学模型来调查疫苗接种计划中对女孩的负面偏见对hbv诱导感染和死亡率的影响。结果:模型模拟显示,将疫苗接种率从80%提高到90%的10%可能有助于显着降低儿童中hbv诱导的感染率(约40%)。如果疫苗接种率从90%提高到95%,再提高5%,乙肝病毒感染率就可能再降低22%。同样,如果将目前的疫苗接种率从80%提高到90%提高10%,未来(2050年以后)乙肝病毒引起的死亡率有可能降低44%,而将目前的疫苗接种率提高5%(90-95%)可能导致死亡率进一步降低24%。这些结果强调了疫苗接种在减少儿童中hbv诱导感染和成人未来死亡率方面的重大影响。此外,在疫苗接种率达到90%的情况下,对女孩接种疫苗的负面偏见导致女性受试者的乙肝病毒感染和死亡率分别比男性受试者增加15%和12%。结论:未及时接种、退出接种计划以及接种计划中对女孩的负面偏见进一步加剧了目前疫苗接种覆盖率(80-90%)。因此,根据可持续发展目标的指导方针,如果目前的情况持续下去,到2030年就不可能实现减少艾滋病毒感染和死亡率的目标。此外,疫苗接种计划中的负偏倚可能会加剧hbv诱导的感染和未来的死亡率。临床意义:根据数学模型,我们建议将疫苗接种率提高到95%,不存在对女孩的负面偏见。为实现这一目标,有关当局必须确保及时和全面完成乙型肝炎病毒疫苗接种计划,减少疫苗接种计划的辍学率,最后防止对女孩的负面偏见,以在性别平等的情况下将疫苗接种覆盖率提高到95%以上。如果没有这些战略,根据可持续发展目标的指示,孟加拉国可能无法实现必要的减少乙肝病毒引起的感染率和死亡率。如何引用本文:Chakraborty S, Chakravorty R, Alam S等。疫苗接种对孟加拉国乙型肝炎病毒感染和死亡率影响的动态数学模型揭示。中华肝病杂志2019;9(2):84-90。
{"title":"A Dynamic Mathematical Modeling Revelation about the Impact of Vaccination on Hepatitis B Virus-induced Infection and Death Rate in Bangladesh.","authors":"Sajib Chakraborty,&nbsp;Rajib Chakravorty,&nbsp;Saruar Alam,&nbsp;Yearul Kabir,&nbsp;Musarrat Mahtab,&nbsp;Md Atikul Islam,&nbsp;Md Abul Khair Yusuf,&nbsp;Ruksana Raihan,&nbsp;Mamun Al Mahtab,&nbsp;Sheikh Mohammad Fazle Akbar","doi":"10.5005/jp-journals-10018-1303","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1303","url":null,"abstract":"<p><strong>Aim: </strong>Attainment of sustainable development goal (SDG) targets requires reducing the rate of new hepatitis B virus (HBV)-induced infection and mortality rate to 90% and 65%, respectively, by 2030. Therefore, it is important to investigate the feasibility of reducing the required rates of HBV-induced infection and death incidents at the current rate of vaccination coverage in Bangladesh. Moreover, factors influencing vaccination coverage like negative bias toward girls during immunization can affect the current vaccination program and ultimately hinder the efforts to reduce HBV-induced infection and death rates. To investigate the possibility of reducing HBV-induced infection and death rates with current vaccination coverage, we adopted mathematical molding-based approach.</p><p><strong>Materials and methods: </strong>We developed a mathematical model based on the susceptible-infectious-recovered model to simulate the HBV-induced infection in children under the age of five at three different vaccination rates: 80, 90, and 95%. Additionally the impact of current vaccination coverage was assessed on HBV-induced death rates in the future. Moreover, we took advantage of the mathematical model to investigate the impact of negative bias toward girls in vaccination program on HBV-induced infection and death rates.</p><p><strong>Results: </strong>The model simulations revealed that 10% increase in the vaccination rate from 80 to 90% can potentially contribute to the significant lowering (around 40%) of HBV-induced infection rate among children. When increased by 5% of vaccination rate from 90 to 95%, the HBV-infection rate is likely to be decreased by another 22%. Likewise, 44% reduction in HBV-induced death rate in the future (2050 onward) can potentially be achieved by 10% increase in the current vaccination rate from 80 to 90%, whereas 5% increase in the current vaccination rate (90-95%) may lead to 24% further reduction of death rate. These results underscored the significant impact of vaccination in reducing HBV-induced infection among children and future death rates in adults. Moreover, at 90% vaccination coverage, the negative bias of vaccination toward girls contributes to an increase of 15 and 12% of HBV-induced infection and death rates, respectively, in female subjects compared to their male counterparts.</p><p><strong>Conclusion: </strong>The current vaccination coverage (80-90%) is further aggravated by untimely vaccination, dropouts from vaccination program, and negative bias toward girls in vaccination program. Therefore, if the current situation persists, it will not be possible to accomplish the required reduction in HBV-induced infection and death rates by 2030, according to the SDG guidelines. Moreover negative bias in the vaccination program may intensify the HBV-induced infection and death rates in the future.</p><p><strong>Clinical significance: </strong>In light of the mathematical model, we suggest that the vacci","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"9 2","pages":"84-90"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d8/28/ejohg-9-84.PMC7047315.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37693909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Relation of Reduction of Antibodies against Hepatitis B Virus to Hepatocellular Carcinoma Recurrence in the Patients with Resolved Hepatitis B Virus Infection Following Direct-acting Antiviral Therapy for Hepatitis C Virus Infection. 丙型肝炎病毒直接抗病毒治疗后乙型肝炎病毒感染消退患者抗乙型肝炎病毒抗体降低与肝癌复发的关系
Pub Date : 2019-07-01 DOI: 10.5005/jp-journals-10018-1305
Kouji Joko, Toshie Mashiba, Hironori Ochi, Ryo Yano, Kaori Sato, Yusuke Okujima, Michiko Aono, Nobuaki Azemoto, Shunji Takechi, Tomoyuki Yokota, Ryosuke Jinoka, Yasunori Moriyama, Masataka Nishiyama

Background: A possible interaction of hepatitis viruses at cellular and molecular levels has been suggested. Eradication of hepatitis C virus (HCV) has been reported to induce activation of hepatitis B virus (HBV)-related liver diseases.

Materials and methods: The present study examined association of HBV markers with recurrence of hepatocellular carcinoma (HCC) in patients with resolved HCV infection by direct-acting antiviral (DAA) therapy. In a patient pool of 378 patients with sustained virologic response (SVR) by DAA, the antibody to the hepatitis B surface antigen (anti-HBs), the antibody to the hepatitis B core antigen (anti-HBc), and HBV-DNA levels were estimated before and at the end of DAA therapy. These patients were HBsAg negative. Eighty-nine patients had a history of curative treatment of HCC by resection or radiofrequency ablation. A Cox proportional hazards model was used to identify risk factors for HCC recurrence, including the change ratio of the antibody against HBV proteins.

Results: Although 188 patients had resolved HBV infection, no patient showed HBV reactivation, but anti-HBs and anti-HBc levels decreased significantly. No significant difference in the HCC recurrence rate was evident between patients with and without resolved HBV infection. Changes of immune responses to HBV proteins did not affect HCC recurrence after DAA therapy for HCV infection in this cohort.

Conclusion: The mechanisms underlying diverse roles of DAA-induced SVR of HCV on HBV kinetics need to be resolved in future.

How to cite this article: Joko K, Mashiba T, Ochi H, et al. Relation of Reduction of Antibodies against Hepatitis B Virus to Hepatocellular Carcinoma Recurrence in the Patients with Resolved Hepatitis B Virus Infection Following Direct-acting Antiviral Therapy for Hepatitis C Virus Infection. Euroasian J Hepato-Gastroenterol 2019;9(2):78-83.

背景:肝炎病毒可能在细胞和分子水平上相互作用。据报道,根除丙型肝炎病毒(HCV)可诱导乙型肝炎病毒(HBV)相关肝脏疾病的激活。材料和方法:本研究探讨了直接作用抗病毒(DAA)治疗的HCV感染消退患者中HBV标志物与肝细胞癌(HCC)复发的关系。在378例DAA持续病毒学应答(SVR)的患者池中,在DAA治疗前和结束时评估乙型肝炎表面抗原抗体(anti-HBs),乙型肝炎核心抗原抗体(anti-HBc)和HBV-DNA水平。这些患者均为HBsAg阴性。89例患者有肝癌切除术或射频消融术的根治史。采用Cox比例风险模型确定HCC复发的危险因素,包括抗HBV蛋白抗体的变化比例。结果:188例患者HBV感染得到缓解,无患者出现HBV再活化,但anti-HBs和anti-HBc水平明显下降。HBV感染消退和未消退患者的HCC复发率无明显差异。在该队列中,对HBV蛋白免疫反应的改变不影响丙肝感染DAA治疗后的HCC复发。结论:daa诱导的HCV SVR对HBV动力学的不同作用机制有待进一步研究。如何引用本文:Joko K, Mashiba T, Ochi H,等。丙型肝炎病毒直接抗病毒治疗后乙型肝炎病毒感染消退患者抗乙型肝炎病毒抗体降低与肝癌复发的关系中华肝病杂志,2019;9(2):78-83。
{"title":"Relation of Reduction of Antibodies against Hepatitis B Virus to Hepatocellular Carcinoma Recurrence in the Patients with Resolved Hepatitis B Virus Infection Following Direct-acting Antiviral Therapy for Hepatitis C Virus Infection.","authors":"Kouji Joko,&nbsp;Toshie Mashiba,&nbsp;Hironori Ochi,&nbsp;Ryo Yano,&nbsp;Kaori Sato,&nbsp;Yusuke Okujima,&nbsp;Michiko Aono,&nbsp;Nobuaki Azemoto,&nbsp;Shunji Takechi,&nbsp;Tomoyuki Yokota,&nbsp;Ryosuke Jinoka,&nbsp;Yasunori Moriyama,&nbsp;Masataka Nishiyama","doi":"10.5005/jp-journals-10018-1305","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1305","url":null,"abstract":"<p><strong>Background: </strong>A possible interaction of hepatitis viruses at cellular and molecular levels has been suggested. Eradication of hepatitis C virus (HCV) has been reported to induce activation of hepatitis B virus (HBV)-related liver diseases.</p><p><strong>Materials and methods: </strong>The present study examined association of HBV markers with recurrence of hepatocellular carcinoma (HCC) in patients with resolved HCV infection by direct-acting antiviral (DAA) therapy. In a patient pool of 378 patients with sustained virologic response (SVR) by DAA, the antibody to the hepatitis B surface antigen (anti-HBs), the antibody to the hepatitis B core antigen (anti-HBc), and HBV-DNA levels were estimated before and at the end of DAA therapy. These patients were HBsAg negative. Eighty-nine patients had a history of curative treatment of HCC by resection or radiofrequency ablation. A Cox proportional hazards model was used to identify risk factors for HCC recurrence, including the change ratio of the antibody against HBV proteins.</p><p><strong>Results: </strong>Although 188 patients had resolved HBV infection, no patient showed HBV reactivation, but anti-HBs and anti-HBc levels decreased significantly. No significant difference in the HCC recurrence rate was evident between patients with and without resolved HBV infection. Changes of immune responses to HBV proteins did not affect HCC recurrence after DAA therapy for HCV infection in this cohort.</p><p><strong>Conclusion: </strong>The mechanisms underlying diverse roles of DAA-induced SVR of HCV on HBV kinetics need to be resolved in future.</p><p><strong>How to cite this article: </strong>Joko K, Mashiba T, Ochi H, <i>et al</i>. Relation of Reduction of Antibodies against Hepatitis B Virus to Hepatocellular Carcinoma Recurrence in the Patients with Resolved Hepatitis B Virus Infection Following Direct-acting Antiviral Therapy for Hepatitis C Virus Infection. Euroasian J Hepato-Gastroenterol 2019;9(2):78-83.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"9 2","pages":"78-83"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/70/8b/ejohg-9-78.PMC7047307.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37693907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Enigmatic Liver Mass in a Child. 一名儿童的神秘肝脏肿块。
Pub Date : 2019-07-01 DOI: 10.5005/jp-journals-10018-1307
Ravi Thanage, Shubham Jain, Nikhil Sonthalia, Suhas Udgirkar, Sanjay Chandnani, Qais Contractor, Pravin Rathi

Hepatic space occupying lesions in childhood are a diagnostic challenge, as they are caused by a variety of malignant and nonmalignant disorders with a different prognosis and, of course, treatment. They are often misdiagnosed or diagnosed only after surgical resection. A 14-year-old boy presented with abdominal pain, evening-rise fever with loss of appetite and weight. The patient also developed jaundice after 2 months of above symptoms. Ultrasound of the abdomen showed an irregular infiltrative mass in segment IV of the liver. Gadobenate disodium magnetic resonance imaging done showed T1 hypointense and T2 hyperintense lesions in segment VIII of the liver with extension into porta with delayed enhancement suggestive of fibrous tumor. Liver biopsy showed extensive liver parenchymal fibrosis with a mixed inflammatory infiltrate with eosinophils. Bacterial, tubercular, and fungal culture of liver biopsy were negative. Although serum IgG4 levels were 7.88 g/L (N =1.9 g/L), IgG4 staining of liver biopsy was negative. The patient was started on prednisolone 1 mg/kg considering the diagnosis of inflammatory pseudotumor (IPT). Twenty days after starting the steroid, mass lesions were converted into multicystic abscess requiring antibiotics and pigtail drainage. On follow-up, patient had improved symptoms with mass lesions turned into small-sized abscess cavity. Hepatic IPTs are difficult to differentiate from malignant tumors, as they are rare and can have variable imaging findings. To avoid inadvertent surgery, histological confirmation of the hepatic mass is essential. Steroids should be used with caution with close follow-up to prevent iatrogenic complications, such as a chronic liver abscess.

How to cite this article: Thanage R, Jain S, Sonthalia N, et al. An Enigmatic Liver Mass in a Child. Euroasian J Hepato-Gastroenterol 2019;9(2):104-107.

儿童期肝占位性病变是一项诊断挑战,因为它们是由各种恶性和非恶性疾病引起的,预后不同,当然,治疗方法也不同。它们经常被误诊或在手术切除后才被诊断出来。一个14岁的男孩表现为腹痛,晚起发烧,食欲不振和体重下降。患者出现上述症状2个月后出现黄疸。腹部超声示肝脏第四节不规则浸润性肿块。钆苯二钠磁共振成像显示肝脏VIII节段T1低信号和T2高信号病变,延伸至门静脉,延迟增强提示纤维性肿瘤。肝活检显示广泛的肝实质纤维化伴嗜酸性粒细胞混合炎症浸润。肝活检细菌、结核和真菌培养均为阴性。虽然血清IgG4水平为7.88 g/L (N =1.9 g/L),但肝活检IgG4染色为阴性。考虑到诊断为炎性假瘤(IPT),患者开始使用强的松龙1mg /kg。开始使用类固醇20天后,肿块病变转化为多囊脓肿,需要抗生素和尾纤引流。随访时,患者症状好转,肿块性病变为小脓肿腔。肝脏ipt很难与恶性肿瘤区分,因为它们很罕见,并且可能有不同的影像学表现。为避免意外手术,肝脏肿块的组织学确认是必要的。应谨慎使用类固醇,并密切随访,以防止医源性并发症,如慢性肝脓肿。如何引用本文:Thanage R, Jain S, Sonthalia N,等。一名儿童的神秘肝脏肿块。中华肝病杂志,2019;9(2):104-107。
{"title":"An Enigmatic Liver Mass in a Child.","authors":"Ravi Thanage,&nbsp;Shubham Jain,&nbsp;Nikhil Sonthalia,&nbsp;Suhas Udgirkar,&nbsp;Sanjay Chandnani,&nbsp;Qais Contractor,&nbsp;Pravin Rathi","doi":"10.5005/jp-journals-10018-1307","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1307","url":null,"abstract":"<p><p>Hepatic space occupying lesions in childhood are a diagnostic challenge, as they are caused by a variety of malignant and nonmalignant disorders with a different prognosis and, of course, treatment. They are often misdiagnosed or diagnosed only after surgical resection. A 14-year-old boy presented with abdominal pain, evening-rise fever with loss of appetite and weight. The patient also developed jaundice after 2 months of above symptoms. Ultrasound of the abdomen showed an irregular infiltrative mass in segment IV of the liver. Gadobenate disodium magnetic resonance imaging done showed T1 hypointense and T2 hyperintense lesions in segment VIII of the liver with extension into porta with delayed enhancement suggestive of fibrous tumor. Liver biopsy showed extensive liver parenchymal fibrosis with a mixed inflammatory infiltrate with eosinophils. Bacterial, tubercular, and fungal culture of liver biopsy were negative. Although serum IgG4 levels were 7.88 g/L (<i>N</i> =1.9 g/L), IgG4 staining of liver biopsy was negative. The patient was started on prednisolone 1 mg/kg considering the diagnosis of inflammatory pseudotumor (IPT). Twenty days after starting the steroid, mass lesions were converted into multicystic abscess requiring antibiotics and pigtail drainage. On follow-up, patient had improved symptoms with mass lesions turned into small-sized abscess cavity. Hepatic IPTs are difficult to differentiate from malignant tumors, as they are rare and can have variable imaging findings. To avoid inadvertent surgery, histological confirmation of the hepatic mass is essential. Steroids should be used with caution with close follow-up to prevent iatrogenic complications, such as a chronic liver abscess.</p><p><strong>How to cite this article: </strong>Thanage R, Jain S, Sonthalia N, <i>et al</i>. An Enigmatic Liver Mass in a Child. Euroasian J Hepato-Gastroenterol 2019;9(2):104-107.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"9 2","pages":"104-107"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/88/a4/ejohg-9-104.PMC7047306.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37693914","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on Immunosuppression in Liver Transplantation. 肝移植免疫抑制研究进展
Pub Date : 2019-07-01 DOI: 10.5005/jp-journals-10018-1301
Burcak E Tasdogan, Michelle Ma, Cem Simsek, Behnam Saberi, Ahmet Gurakar

The standard therapy for decompensated end-stage chronic liver disease of any etiology and acute fulminant hepatic failure is liver transplantation (LT). Advances in immunosuppressive therapy decreased the rates of acute and chronic rejections. Thus, graft and patient survivals have significantly improved. However, long-term adverse effects of prolonged use of immunosuppressive agents such as malignancies, opportunistic infections, metabolic disorders, and other organ toxicities have now become a major concern. Consequently, alternative approaches are needed to deescalate the customary drugs and their side effects. Therapy must be individualized and additional preventive measures should be taken by patients with particular risk factors or predisposed to certain adverse effects. Current opinion favors a combination of agents with different mechanism of actions and toxicity profiles. Corticosteroids are employed in immediate and early postoperative period. Although they have a pronounced side effect profile, calcineurin inhibitors (CNIs) are still the backbone of early and late phase immunosuppressive regimens because of their proved efficacy. Antimetabolites are frequent choices for steroid and/or CNI-sparing strategies. Studies also have established a role for mammalian target of rapamycin (mTOR) inhibitors in specific groups of recipients. Biologic agents are a hot topic of interest and made their way into current strategies for induction. Agents extrapolated from other transplantation or immunologic experience are being evaluated.

How to cite this article: Tasdogan BE, Ma M, Simsek C, et al. Update on Immunosuppression in Liver Transplantation. Euroasian J Hepato-Gastroenterol 2019;9(2):96-101.

任何病因的失代偿终末期慢性肝病和急性暴发性肝衰竭的标准治疗是肝移植(LT)。免疫抑制疗法的进步降低了急性和慢性排斥反应的发生率。因此,移植物和病人的存活率有了显著的提高。然而,长期使用免疫抑制剂的长期副作用,如恶性肿瘤、机会性感染、代谢紊乱和其他器官毒性,现在已成为一个主要关注的问题。因此,需要其他方法来降低常用药物及其副作用。治疗必须个体化,对于有特殊危险因素或易发生某些不良反应的患者,应采取额外的预防措施。目前的观点倾向于使用具有不同作用机制和毒性特征的药物组合。术后即刻和早期使用皮质类固醇。尽管钙调磷酸酶抑制剂(CNIs)具有明显的副作用,但由于其已证实的有效性,它们仍然是早期和晚期免疫抑制方案的骨干。抗代谢物是类固醇和/或cni保护策略的常用选择。研究还确定了哺乳动物雷帕霉素靶点(mTOR)抑制剂在特定受体群体中的作用。生物制剂是人们感兴趣的一个热门话题,并已成为当前诱导策略的一部分。正在评估从其他移植或免疫经验推断出的药物。如何引用本文:Tasdogan BE, Ma M, Simsek C,等。肝移植免疫抑制研究进展中华肝病与胃肠病杂志2019;9(2):96-101。
{"title":"Update on Immunosuppression in Liver Transplantation.","authors":"Burcak E Tasdogan,&nbsp;Michelle Ma,&nbsp;Cem Simsek,&nbsp;Behnam Saberi,&nbsp;Ahmet Gurakar","doi":"10.5005/jp-journals-10018-1301","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1301","url":null,"abstract":"<p><p>The standard therapy for decompensated end-stage chronic liver disease of any etiology and acute fulminant hepatic failure is liver transplantation (LT). Advances in immunosuppressive therapy decreased the rates of acute and chronic rejections. Thus, graft and patient survivals have significantly improved. However, long-term adverse effects of prolonged use of immunosuppressive agents such as malignancies, opportunistic infections, metabolic disorders, and other organ toxicities have now become a major concern. Consequently, alternative approaches are needed to deescalate the customary drugs and their side effects. Therapy must be individualized and additional preventive measures should be taken by patients with particular risk factors or predisposed to certain adverse effects. Current opinion favors a combination of agents with different mechanism of actions and toxicity profiles. Corticosteroids are employed in immediate and early postoperative period. Although they have a pronounced side effect profile, calcineurin inhibitors (CNIs) are still the backbone of early and late phase immunosuppressive regimens because of their proved efficacy. Antimetabolites are frequent choices for steroid and/or CNI-sparing strategies. Studies also have established a role for mammalian target of rapamycin (mTOR) inhibitors in specific groups of recipients. Biologic agents are a hot topic of interest and made their way into current strategies for induction. Agents extrapolated from other transplantation or immunologic experience are being evaluated.</p><p><strong>How to cite this article: </strong>Tasdogan BE, Ma M, Simsek C, <i>et al</i>. Update on Immunosuppression in Liver Transplantation. Euroasian J Hepato-Gastroenterol 2019;9(2):96-101.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"9 2","pages":"96-101"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/63/ae/ejohg-9-96.PMC7047305.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37693910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 23
Valproate-induced Drug Rash Eosinophilia with Systemic Symptoms Syndrome: An Unknown Hepatotoxicity. 丙戊酸盐引起的药物性皮疹嗜酸性粒细胞增多伴全身症状综合征:一种未知的肝毒性。
Pub Date : 2019-07-01 DOI: 10.5005/jp-journals-10018-1298
Tarana Gupta

Drug rash eosinophilia with systemic symptoms (DRESS syndrome) presents as an acute febrile illness with leukocytosis, eosinophilia, lymphadenopathy, skin rash with acute hepatitis, renal failure, myositis, or systemic organ involvement. Aromatic anticonvulsants like phenytoin, carbamazepine, and phenobarbital cause drug-induced hypersensitivity or DRESS syndrome. However, sodium valproate being nonaromatic compound although known hepatotoxic drug in preexisting chronic liver disease has never been reported to cause DRESS syndrome alone. Here we report an interesting case of DRESS syndrome caused by valproate, which presented as an acute hepatitis illness with rash, renal dysfunction, and typical hematological features of DRESS syndrome within 2 months of the introduction of the drug in an epileptic patient. Patient initially showed a good response to intravenous steroids with improvement in the liver and renal dysfunction. However, later on, developed pancytopenia either due to steroid-induced sepsis or DRESS syndrome-related secondary hemophagocytosis (HPS) due to involvement of bone marrow as a rare occurrence and succumbed to illness.

How to cite this article: Gupta T. Valproate-induced Drug Rash Eosinophilia with Systemic Symptoms Syndrome: An Unknown Hepatotoxicity. Euroasian J Hepato-Gastroenterol 2019;9(2):102-103.

药物疹性嗜酸性粒细胞增多伴全身性症状(DRESS综合征)表现为急性发热性疾病,伴白细胞增多、嗜酸性粒细胞增多、淋巴结病、皮疹伴急性肝炎、肾功能衰竭、肌炎或全身器官受累。芳香类抗惊厥药如苯妥英、卡马西平和苯巴比妥可引起药物致过敏反应或DRESS综合征。然而,丙戊酸钠是一种非芳香族化合物,虽然已知是用于既往慢性肝病的肝毒性药物,但从未有单独引起DRESS综合征的报道。在这里,我们报告一个有趣的由丙戊酸引起的DRESS综合征病例,该病例在癫痫患者引入该药后2个月内表现为急性肝炎疾病,伴有皮疹、肾功能障碍和典型的DRESS综合征血液学特征。患者最初对静脉注射类固醇反应良好,肝肾功能改善。然而,后来,由于类固醇诱导的败血症或由于累及骨髓的DRESS综合征相关继发性噬血细胞症(HPS)而发生全血细胞减少症,这是罕见的,并死于疾病。丙戊酸盐引起的药物性皮疹嗜酸性粒细胞增多伴全身症状综合征:一种未知的肝毒性。中华肝病杂志;2019;9(2):102-103。
{"title":"Valproate-induced Drug Rash Eosinophilia with Systemic Symptoms Syndrome: An Unknown Hepatotoxicity.","authors":"Tarana Gupta","doi":"10.5005/jp-journals-10018-1298","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1298","url":null,"abstract":"<p><p>Drug rash eosinophilia with systemic symptoms (DRESS syndrome) presents as an acute febrile illness with leukocytosis, eosinophilia, lymphadenopathy, skin rash with acute hepatitis, renal failure, myositis, or systemic organ involvement. Aromatic anticonvulsants like phenytoin, carbamazepine, and phenobarbital cause drug-induced hypersensitivity or DRESS syndrome. However, sodium valproate being nonaromatic compound although known hepatotoxic drug in preexisting chronic liver disease has never been reported to cause DRESS syndrome alone. Here we report an interesting case of DRESS syndrome caused by valproate, which presented as an acute hepatitis illness with rash, renal dysfunction, and typical hematological features of DRESS syndrome within 2 months of the introduction of the drug in an epileptic patient. Patient initially showed a good response to intravenous steroids with improvement in the liver and renal dysfunction. However, later on, developed pancytopenia either due to steroid-induced sepsis or DRESS syndrome-related secondary hemophagocytosis (HPS) due to involvement of bone marrow as a rare occurrence and succumbed to illness.</p><p><strong>How to cite this article: </strong>Gupta T. Valproate-induced Drug Rash Eosinophilia with Systemic Symptoms Syndrome: An Unknown Hepatotoxicity. Euroasian J Hepato-Gastroenterol 2019;9(2):102-103.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"9 2","pages":"102-103"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/05/40/ejohg-9-102.PMC7047308.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37693911","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
High Prevalence of Wilson's Diseases with Low Prevalence of Kayser-Fleischer Rings among Patients with Cryptogenic Chronic Liver Diseases in Bangladesh. 在孟加拉国的隐源性慢性肝病患者中,威尔森病的高患病率与凯瑟-弗莱舍环的低患病率
Pub Date : 2019-07-01 DOI: 10.5005/jp-journals-10018-1299
Nuzhat Choudhury, Shamshad B Quraishi, Akm Atiqullah, Md Sakirul Islam Khan, Mamun Al Mahtab, Sheikh Mf Akbar

Background: Chronic liver disease (CLD) is common in Bangladesh; however, a major bulk remains as cryptogenic CLD as they remain devoid of known pathological agents leading to have a check of Kayser-Fleischer (K-F) rings for possible Wilson's disease (WD) and many of these patients develop complications such as cirrhosis of liver and hepatocellular carcinoma. However, there remains considerable proportions of CLD patients with undefined etiology (cryptogenic CLD) and these patients cannot be provided effective therapy based on etiological factors. Here, the proportion of WD among cryptogenic CLD patients in Bangladesh has been evaluated to improve the management of CLD and reduce complications.

Materials and methods: A total of 941 patients with cryptogenic CLD [negative for hepatitis viruses, alcohol, nonalcoholic fatty liver disease (NAFLD), drug, and autoimmunity] were enrolled in the study. To assess if they have been suffering from WD, the levels of copper in 24-hour urine were evaluated. Definitive WD was diagnosed when 24-hour urinary copper output was >100 μg and strongly indicative WD patients excreted >40 μg of copper in 24 hours.

Results: Out of 941 patients with cryptogenic CLD, 212 patients were diagnosed as definitive WD and 239 patients as strongly indicative WD on the basis of 24-hours copper excretion. The age distribution ranging of the patients varied from 1 year to 90 years. There was a male predominance. Considerable numbers of WD patients had previous history of jaundice. Kayser-Fleischer rings were mostly uncommon and detected in five patients with WD only.

Discussion: Wilson's disease is not a rare entity in Bangladesh; rather, it seems to be fairly common among CLD patients. A country-wide epidemiological survey should be conducted for diagnosis of WD in Bangladesh to provide a proper management strategy for these huge numbers of WD patients. In fact, most of the WD patients are unaware of their diagnosis and the general physicians are equally unaware of diagnosis and management of WD.

How to cite this article: Choudhury N, Quraishi SB, Atiqullah AKM, et al. High Prevalence of Wilson's Diseases with Low Prevalence of Kayser-Fleischer Rings among Patients with Cryptogenic Chronic Liver Diseases in Bangladesh. Euroasian J Hepato-Gastroenterol 2019;9(2):67-70.

背景:慢性肝病(CLD)在孟加拉国很常见;然而,大部分仍然是隐源性CLD,因为它们仍然缺乏已知的病理因子,导致需要检查可能的威尔逊病(WD)的Kayser-Fleischer (K-F)环,其中许多患者出现并发症,如肝硬化和肝细胞癌。然而,仍有相当比例的CLD患者病因不明(隐源性CLD),这些患者无法根据病因提供有效的治疗。在这里,我们评估了孟加拉国隐源性CLD患者中WD的比例,以改善CLD的管理并减少并发症。材料和方法:共有941例隐源性CLD患者[肝炎病毒、酒精、非酒精性脂肪性肝病(NAFLD)、药物和自身免疫阴性]被纳入研究。为了评估他们是否患有WD,对24小时尿液中的铜含量进行了评估。24小时尿铜排泄量>100 μg时诊断为明确的WD,强烈指示性WD患者24小时铜排泄量>40 μg。结果:在941例隐源性CLD患者中,根据24小时铜排泄,212例患者被诊断为明确WD, 239例患者被诊断为强烈指示性WD。患者年龄分布从1岁到90岁不等。男性占优势。相当数量的WD患者既往有黄疸病史。Kayser-Fleischer环大多不常见,仅在5例WD患者中检测到。讨论:威尔逊病在孟加拉国并不罕见;相反,它似乎在CLD患者中相当普遍。孟加拉国应开展全国范围的流行病学调查以诊断WD,为这些庞大的WD患者提供适当的管理策略。事实上,大多数WD患者不知道自己的诊断,普通医生同样不知道WD的诊断和治疗。本文引用方式:Choudhury N, Quraishi SB, Atiqullah AKM等。在孟加拉国的隐源性慢性肝病患者中,威尔森病的高患病率与凯瑟-弗莱舍环的低患病率中华肝病杂志,2019;9(2):67-70。
{"title":"High Prevalence of Wilson's Diseases with Low Prevalence of Kayser-Fleischer Rings among Patients with Cryptogenic Chronic Liver Diseases in Bangladesh.","authors":"Nuzhat Choudhury,&nbsp;Shamshad B Quraishi,&nbsp;Akm Atiqullah,&nbsp;Md Sakirul Islam Khan,&nbsp;Mamun Al Mahtab,&nbsp;Sheikh Mf Akbar","doi":"10.5005/jp-journals-10018-1299","DOIUrl":"https://doi.org/10.5005/jp-journals-10018-1299","url":null,"abstract":"<p><strong>Background: </strong>Chronic liver disease (CLD) is common in Bangladesh; however, a major bulk remains as cryptogenic CLD as they remain devoid of known pathological agents leading to have a check of Kayser-Fleischer (K-F) rings for possible Wilson's disease (WD) and many of these patients develop complications such as cirrhosis of liver and hepatocellular carcinoma. However, there remains considerable proportions of CLD patients with undefined etiology (cryptogenic CLD) and these patients cannot be provided effective therapy based on etiological factors. Here, the proportion of WD among cryptogenic CLD patients in Bangladesh has been evaluated to improve the management of CLD and reduce complications.</p><p><strong>Materials and methods: </strong>A total of 941 patients with cryptogenic CLD [negative for hepatitis viruses, alcohol, nonalcoholic fatty liver disease (NAFLD), drug, and autoimmunity] were enrolled in the study. To assess if they have been suffering from WD, the levels of copper in 24-hour urine were evaluated. Definitive WD was diagnosed when 24-hour urinary copper output was >100 μg and strongly indicative WD patients excreted >40 μg of copper in 24 hours.</p><p><strong>Results: </strong>Out of 941 patients with cryptogenic CLD, 212 patients were diagnosed as definitive WD and 239 patients as strongly indicative WD on the basis of 24-hours copper excretion. The age distribution ranging of the patients varied from 1 year to 90 years. There was a male predominance. Considerable numbers of WD patients had previous history of jaundice. Kayser-Fleischer rings were mostly uncommon and detected in five patients with WD only.</p><p><strong>Discussion: </strong>Wilson's disease is not a rare entity in Bangladesh; rather, it seems to be fairly common among CLD patients. A country-wide epidemiological survey should be conducted for diagnosis of WD in Bangladesh to provide a proper management strategy for these huge numbers of WD patients. In fact, most of the WD patients are unaware of their diagnosis and the general physicians are equally unaware of diagnosis and management of WD.</p><p><strong>How to cite this article: </strong>Choudhury N, Quraishi SB, Atiqullah AKM, <i>et al</i>. High Prevalence of Wilson's Diseases with Low Prevalence of Kayser-Fleischer Rings among Patients with Cryptogenic Chronic Liver Diseases in Bangladesh. Euroasian J Hepato-Gastroenterol 2019;9(2):67-70.</p>","PeriodicalId":11992,"journal":{"name":"Euroasian Journal of Hepato-Gastroenterology","volume":"9 2","pages":"67-70"},"PeriodicalIF":0.0,"publicationDate":"2019-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/41/76/ejohg-9-67.PMC7047311.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37692974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Euroasian Journal of Hepato-Gastroenterology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1